8-K: Tvardi Therapeutics: STAT3 Inhibitors Advance in HCC & Fibrosis

Tvardi Therapeutics, Inc. provided a corporate presentation detailing encouraging interim Phase 1b/2 data for TTI-101 in hepatocellular carcinoma and progress on its next-generation STAT3 inhibitor, TTI-109.

Summary

• Tvardi Therapeutics, Inc. (TVRD) released an updated corporate presentation on November 19, 2025, highlighting its pipeline and clinical progress.
• The company is focused on targeting STAT3, a central mediator in fibrosis-driven diseases, leveraging deep expertise in STAT3 biology.
• TTI-101, a STAT3 inhibitor, showed encouraging interim Phase 1b/2 data in hepatocellular carcinoma (HCC), demonstrating clinically meaningful activity in both monotherapy and combination therapy.
• In the REVERTLiver Cancer Phase 1b/2 study, interim data (as of August 2024) reported Objective Response Rates (ORR) of 33% for monotherapy (Cohort A), 50% for TTI-101 + Pembrolizumab (Cohort B), and 33% for TTI-101 + Atezo/Bev (Cohort C).
• These early results compare favorably to third-party trials; for instance, Cohort C's 33% ORR exceeded IMBrave150's 27% ORR, despite IMBrave150 having a higher proportion of HBV-associated HCC patients who typically show greater benefit.
• TTI-101 demonstrated durable partial responses in fibrotic tumors in a Phase 1 monotherapy study, with two HCC patients sustaining responses for 10 and 14 months.
• The company is developing TTI-109, a next-generation phosphate prodrug of TTI-101, designed for enhanced delivery and improved tolerability, with an Investigational New Drug (IND) application filed in June 2025 and a Phase 1 healthy volunteer trial ongoing.
• Key upcoming milestones include topline data from the TTI-101 Phase 2 HCC trial and TTI-109 Phase 1 healthy volunteer data, both expected in 1H:2026.
• As of September 30, 2025, Tvardi had $36.5 million in cash, cash equivalents, and short-term investments, with an anticipated cash runway into Q4 2026.

Sentiment

Score: 8

Explanation: The corporate presentation provides strong positive interim clinical data for TTI-101 in HCC, showing superior efficacy compared to current standards and competitor trials. The progress on TTI-109 and a clear pipeline with near-term catalysts also contribute to a highly positive outlook, despite the early-stage nature of the data and inherent risks in drug development.

Positives

• TTI-101 demonstrated encouraging interim Phase 1b/2 clinical activity in hepatocellular carcinoma (HCC) across monotherapy and combination regimens.
• Interim Objective Response Rates (ORR) in the REVERTLiver Cancer study were 33% for monotherapy, 50% for TTI-101 + Pembrolizumab, and 33% for TTI-101 + Atezo/Bev.
• These ORRs compare favorably to current standard of care and third-party trials, with TTI-101 + Atezo/Bev (33% ORR) outperforming IMBrave150 (27% ORR) even without the benefit of HBV-associated HCC patients.
• TTI-101 monotherapy showed durable partial responses in Phase 1, with two HCC patients sustaining responses for 10 and 14 months.
• The drug was well-tolerated in Phase 1 with no dose-limiting toxicities (DLTs) and exposures above levels required for preclinical efficacy.
• TTI-101 demonstrated enhanced biological activity in fibrotic cancers, with ORR exceeding the current expected standard of care in 2L HCC (<5%).
• Preclinical data supports TTI-101's dual therapeutic effect on cancer cells by overcoming tumorigenesis and immune suppression, and its ability to reverse established fibrosis and reduce immunosuppressive markers in various fibrosis models.
• The next-generation STAT3 inhibitor, TTI-109, has an IND filed and is undergoing a Phase 1 healthy volunteer study, with preclinical GLP results showing no toxicology findings and rapid conversion to active TTI-101.
• The company has a clear pipeline with multiple near-term data catalysts expected in 1H:2026.
• Anticipated cash runway extends into Q4 2026, providing funding for ongoing operations.

Negatives

• The interim clinical data is preliminary and not subject to the standard quality control measures typically associated with final clinical trial results.
• Cross-study comparisons are inherently limited and may suggest misleading similarities and differences.
• Some treatment-related adverse events (TRAEs) were observed in Phase 1 TTI-101 monotherapy, including diarrhea (up to 20% Grade 3), nausea (up to 14% Grade 3), fatigue, and elevated ALT/AST (up to 14% Grade 3).
• The company is still in clinical development stages, with no approved products on the market.

Risks

• Forward-looking statements involve substantial risks and uncertainties, and actual results or events could differ materially from plans, intentions, and expectations.
• The company may not actually achieve the plans, intentions, or expectations disclosed regarding potential benefits, activity, effectiveness, and safety of product candidates.
• Uncertainties exist regarding the design and results of research and development programs, preclinical studies, and clinical trials, including the timing and availability of data.
• Risks related to preclinical, clinical, and regulatory development plans, including the timing or likelihood of regulatory filings and approvals.
• Uncertainties about the ability to license, acquire, discover, and develop additional product candidates and advance them into and successfully complete preclinical studies and clinical trials.
• Potential market size and size of potential patient populations for product candidates may not be as anticipated.
• Risks related to maintaining existing and establishing new strategic collaborations, licensing, or other arrangements.
• Challenges in establishing and maintaining intellectual property rights covering product candidates.
• Risks associated with business strategy, future results of operations, and financial position.
• Estimates and statistical data relating to market size and growth involve assumptions and limitations, and projections of future performance are subject to a high degree of uncertainty and risk.

Future Outlook

Tvardi Therapeutics anticipates significant clinical milestones in the first half of 2026, including topline data from the Phase 2 REVERTLiver Cancer trial for TTI-101 in hepatocellular carcinoma and Phase 1 healthy volunteer data for its next-generation STAT3 inhibitor, TTI-109. The company expects its current cash and investments to fund operations into Q4 2026, supporting ongoing research and development efforts for its fibrosis-driven disease pipeline.

Management Comments

• Deep expertise in STAT3 biology.
• Potential to serve as a disease-modifying therapy.
• TTI-109: designed to enhance delivery of STAT3 inhibitor & improve tolerability.
• Unlocking highly-validated target within fibrosis-driven diseases.
• Demonstrated target engagement and disease modification across animal models of fibrosis.
• Phase 1 demonstrated enhanced biological activity in fibrotic cancers.
• Phase 2 ongoing in fibrosis-driven HCC evaluating both mono-and combination therapy.

Industry Context

The announcement positions Tvardi Therapeutics at the forefront of targeting STAT3, a highly validated pathway in both oncology and fibrosis, areas with significant unmet medical needs. Hepatocellular carcinoma (HCC) remains a leading cause of cancer deaths globally, with current second and third-line therapies offering limited efficacy. Tvardi's TTI-101, by demonstrating encouraging activity in both monotherapy and combination with immune checkpoint inhibitors (ICIs), offers a differentiated approach compared to existing treatments like TKIs and anti-VEGF therapies. The development of TTI-109 as a next-generation STAT3 inhibitor also reflects an industry trend towards improving drug delivery and tolerability for established mechanisms. The favorable comparison of TTI-101's interim ORR to competitor trials like IMBrave150, especially given the patient population differences, suggests a potentially competitive profile in the challenging HCC landscape.

Comparison to Industry Standards

• TTI-101's Phase 1 monotherapy in HCC showed an Objective Response Rate (ORR) that "exceeds current standard of care in HCC," which is typically <5% for second-line treatment.
• The REVERTLiver Cancer Phase 1b/2 interim data for TTI-101 + Atezo/Bev (Cohort C) demonstrated an ORR of 33%, which compares favorably to the 27% ORR reported for the atezo/bev arm in the IMBrave150 study.
• Notably, REVERTHCC Cohort C had no patients with HBV-associated HCC, whereas 49% of patients in IMBrave150's atezo/bev arm had HBV-associated HCC and demonstrated a higher likelihood of benefit, making Tvardi's results even more compelling in comparison.
• The company highlights that TTI-101's strong rationale for combination with Immune Checkpoint Inhibition (ICI) is supported by preclinical proof-of-concept and a Phase 1 responder who overcame ICI resistance, contrasting with the suspended development of Danvatirsen (another STAT3 ASO) by AZN/Ionis due to observed adverse events, onerous dosing, and poor pharmacodynamics.
• In preclinical models, TTI-101 demonstrated greater modulation of fibrotic genes compared to standard of care in human lung slices for Idiopathic Pulmonary Fibrosis (IPF).

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to positive clinical trial results and advancement of the pipeline. The anticipated cash runway into Q4 2026 provides financial stability for the near-term.
• Patients (HCC & Fibrosis): Potential for new, more effective treatment options, especially in areas of high unmet need like advanced HCC and fibrosis-driven diseases.
• Investment Professionals: Provides updated data and milestones for investment analysis and decision-making.
• Regulatory Authorities: Ongoing clinical trials and IND filings indicate active engagement with regulatory processes.

Next Steps

• Release of topline data from TTI-101 Phase 2 HCC trial in 1H:2026.
• Release of Phase 1 healthy volunteer data for TTI-109 in 1H:2026.
• Additional analysis ongoing for TTI-101 Idiopathic Pulmonary Fibrosis data.
• Continued advancement of TTI-109 Phase 1 trial in healthy volunteers.
• Continued advancement of TTI-101 Phase 2 REVERTLiver Cancer study in HCC.

Key Dates

Recommendation

The interim Phase 1b/2 data for TTI-101 in hepatocellular carcinoma (HCC) is exceptionally strong, demonstrating Objective Response Rates (ORR) significantly above the current standard of care and even outperforming a major competitor's trial (IMBrave150) in a less favorable patient population. The durable responses observed in Phase 1 further underscore TTI-101's potential. The company's deep expertise in STAT3 biology, a highly validated target, combined with the advancement of a next-generation compound (TTI-109) and a clear roadmap of near-term catalysts in 1H 2026, presents a compelling investment thesis. While early-stage data carries inherent risks, the magnitude of the observed clinical benefit and the strategic positioning in high-unmet-need indications suggest substantial upside potential. The cash runway into Q4 2026 provides sufficient operational liquidity for the upcoming milestones.

Keywords

STAT3 inhibitor, Hepatocellular Carcinoma, HCC, Fibrosis, TTI-101, TTI-109, Clinical Trials, Oncology, Drug Development, Biotechnology, Liver Cancer, Idiopathic Pulmonary Fibrosis, IPF, NASH, Immune Checkpoint Inhibition, Combination Therapy